By eliminating circulating CD19 expressing malignant cells, anti-CD19 CAR T-cell therapy, Axicabtagene ciloleucel (Axi-cel, KTE-X19, TecartusTM) is prepared for patients associated with MCL [98]. The gene discussed is CD19; the disease is mantle cell lymphoma.